Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:45 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07082270 · Roswell Park Cancer Institute · PHASE1 · withdrawn · last registry update 2026-05-15 · Multiple myeloma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor withdrawal of supplying investigational drug” | Open Targets' class: logistics resources | Registry record, Roswell Park Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PSMD1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Results posted on the registry: Mayo Clinic, Carfilzomib + Daratumumab (NCT05497804)
- 2026-11-02Results posted on the registry: Joseph Tuscano, Clarithromycin + Dexamethasone (NCT02542657)
- 2026-09-29Results posted on the registry: Hoffmann-La Roche, Forimtamig + Carfilzomib (NCT06055075)
- 2026-09-29Also stopped (terminated): Hoffmann-La Roche, Forimtamig + Carfilzomib (NCT06055075)
- 2026-09-15Results posted on the registry: Academic and Community Cancer Research United, Carfilzomib + Daratumumab (NCT04756401)
- 2026-08-19Phase 3 first posted: CellCentric Ltd., InoPd + Investigator's choice of SAT (NCT07772024)
- 2026-07-27Phase 3 first posted: AbbVie, Etentamig + Pomalidomide (NCT07728188)
- 2026-07-13Also stopped (suspended): Hackensack Meridian Health, Carfilzomib + Iberdomide (NCT05199311)
- 2026-05-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, daratumumab + carfilzomib (NCT03290950)
- 2026-05-13Also stopped (terminated): University Hospital, Caen, Ixazomib and Daratumumab (NCT03757221)
- 2026-05-04Also stopped (terminated): Takeda, Ixazomib + Lenalidomide (NCT03173092)
- 2026-04-29Phase 3 first posted: Hoffmann-La Roche, Cevostamab + Pomalidomide (NCT07555938)
- 2026-03-20Results posted on the registry: Celgene, CC-220 + Dexamethasone (NCT02773030)
- 2026-03-06Results posted on the registry: University of Colorado, Denver, Selinexor + Pomalidomide (NCT04925193)
- 2026-02-10Results posted on the registry: National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2026-02-10Also stopped (terminated): National Cancer Institute (NCI), Carfilzomib + Dexamethasone (NCT03031730)
- 2026-02-06Phase 3 first posted: AstraZeneca, AZD0120 + Daratumumab (NCT07391657)
- 2026-01-29Also stopped (terminated): Teva Branded Pharmaceutical Products R&D LLC, Modakafusp alfa + Lenalidomide (NCT05556616)
- 2026-01-22Results posted on the registry: University of Chicago, Ixazomib Citrate + Lenalidomide (NCT02389517)
- 2026-01-05Also stopped (terminated): Universitätsklinikum Hamburg-Eppendorf, Allogeneic Stem Cells + carfilzomib/lenalidomide/dexamethasone (KRD) (NCT05675319)
- 2025-11-20Results posted on the registry: Memorial Sloan Kettering Cancer Center, Carfilzomib + Lenalidomide (NCT02937571)
- 2025-10-30Phase 3 first posted: Regeneron Pharmaceuticals, Linvoseltamab + Carfilzomib (NCT07222761)
- 2025-10-21Also stopped (terminated): University of California, San Diego, Ixazomib + Pomalidomide (NCT03590652)
- 2025-10-07Also stopped (terminated): University of Pennsylvania, Tasquinimod + IRd chemotherapy (NCT04405167)
- 2025-09-10Results posted on the registry: University of Chicago, Elotuzumab + Carfilzomib (NCT02969837)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision